Catalent, Inc.

    Catalent, Inc.

    NNYSE:CTLT
    63.48
    USD
    0.00
    (0.00%)
    2012 Y
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    14.45
    15.35
    15.58
    15.27
    14.81
    16.6
    18.78
    17.46
    20.65
    23.8
    27.28
    23.55
    24.2
    24.3
    Basic EPS, GAAP
    -0.21
    -0.42
    0.14
    1.77
    0.89
    0.88
    0.64
    0.95
    1.48
    3.48
    2.84
    -1.41
    -5.76
    -2.27
    Free Cash Flow per Basic Share
    -0.14
    0.13
    0.48
    0.26
    0.13
    1.28
    1.51
    0.21
    -0.17
    -1.51
    -1.26
    -1.78
    -0.33
    0.54
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    0.24
    0.13
    0.02
    - -
    - -
    - -
    Book Value per Share
    -11.77
    -11.89
    -11.75
    -9.72
    -8.29
    -7.64
    -6.64
    -5.01
    -3.56
    0.16
    2.95
    1.46
    -4.3
    -4.99
    Tangible Book Value per Share
    -15.33
    -15.39
    -15.57
    -6.64
    -5.25
    -4.75
    -6.52
    -10.19
    -3.08
    3.45
    4.03
    3.27
    2.38
    2.01
    Basic Weighted Avg Shares
    117
    117
    117
    120
    125
    125
    131
    144
    150
    168
    176
    181
    181
    182
    Sales/Revenue/Turnover
    1,695
    1,800
    1,828
    1,831
    1,848
    2,075
    2,463
    2,518
    3,094
    3,998
    4,802
    4,263
    4,381
    4,422
    Operating Margin (%)
    12.94
    12.66
    14.43
    15.18
    12.42
    12.14
    11.68
    10.88
    12.77
    16.16
    15.18
    1.1
    -1.42
    -2.46
    Depreciation Expense
    130
    152
    143
    141
    141
    147
    190
    229
    254
    289
    378
    422
    489
    490
    Net Income, GAAP
    -24
    -50
    16
    212
    112
    110
    84
    137
    221
    585
    499
    -256
    -1,043
    -413
    Effective Tax Rate (%)
    2.69
    - -
    73.44
    - -
    23.26
    19.03
    45
    14.38
    15
    18.18
    13.82
    - -
    - -
    39.47
    Profit Margin (%)
    -1.44
    -2.76
    0.89
    11.59
    6.03
    5.29
    3.39
    5.44
    7.14
    14.63
    10.39
    -6.01
    -23.81
    -9.34
    Working Capital
    265
    269
    235
    339
    399
    591
    663
    725
    1,400
    1,722
    1,819
    1,162
    1,566
    1,509
    LT Debt
    2,640
    2,657
    2,685
    1,857
    1,833
    2,055
    2,649
    2,883
    2,945
    3,166
    4,171
    4,313
    4,857
    4,886
    Total Equity
    -351
    -410
    -372
    634
    636
    724
    1,087
    2,288
    3,506
    4,274
    4,775
    4,611
    3,604
    3,542
    Return on Invested Capital (%)
    18.04
    - -
    2.97
    - -
    6.9
    7.61
    4.76
    5.17
    5.69
    7.5
    7.59
    - -
    - -
    - -
    Return on Capital (%)
    23.45
    - -
    4.6
    - -
    23.33
    18.74
    9.74
    9.66
    11.03
    20
    14.44
    - -
    - -
    20.85
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    182.45
    -65.31
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'25
    ST Debt
    57
    61
    61
    LT Borrowings
    4,933
    4,857
    4,886
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    181
    181
    181
    Market Capitalization
    10,246
    10,215
    11,024

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'25
    Total Current Assets
    2,523
    2,597
    2,507
    Cash, Cash Equivalents & STI
    162
    289
    335
    Accounts Receivable, Net
    875
    921
    760
    Inventories
    770
    603
    583
    Total Current Liabilities
    1,007
    1,031
    998
    Payables & Accruals
    555
    539
    538
    ST Debt
    57
    61
    61
    Deferred Revenue
    249
    250
    272

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    -3.41%
    12.32%
    -21.84%
    Free Cash Flow
    140.02%
    127.56%
    -81.68%
    Net Income, GAAP
    156.84%
    73.49%
    307.42%
    Sales/Revenue/Turnover
    9.81%
    12.75%
    2.77%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    1,022
    1,149
    1,037
    1,055
    4,263
    2024
    982
    1,024
    1,074
    1,301
    4,381
    2025
    1,023
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    0.45
    -1.25
    -0.61
    -1.41
    2024
    -4.19
    -1.13
    -0.55
    - -
    -5.76
    2025
    -0.71
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • businesswire.com

      Catalent and Mantra™ Announce Commercial Supply Agreement for Single-Serve Oral Gel Portfolio

    • reuters.com

      Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

    • globenewswire.com

      Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

    • businesswire.com

      Catalent Launches Qai™ to Reimagine Quality Assurance for its Manufacturing Services

    • businesswire.com

      Cartherics and Catalent Expand Commercial License Agreement

    • businesswire.com

      Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases

    • businesswire.com

      SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs

    • globenewswire.com

      Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

    • businesswire.com

      Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”

    • proactiveinvestors.com

      Lisata Therapeutics CEO discusses Catalent deal - ICYMI

    • proactiveinvestors.com

      Lisata Therapeutics CEO discusses Catalent deal - ICYMI

    • proactiveinvestors.com

      Lisata Therapeutics inks global product license deal with Catalent

    • benzinga.com

      Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection

    • investors.com

      Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug

    • globenewswire.com

      Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research

    • globenewswire.com

      Asia-Pacific Pharmaceutical CMO Market Share Analysis, Trends and Growth Forecasts to 2030 Featuring Catalent, Recipharm, Jubilant Life Sciences and More

    • businesswire.com

      Prolific Machines Appoints Former Catalent Chief Scientific Officer to Board of Directors

    • proactiveinvestors.com

      Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI

    • proactiveinvestors.com

      Lisata Therapeutics signs research license with Catalent

    • globenewswire.com

      Lisata Therapeutics Announces Research License with Catalent